Physician profile
Craig E Johnson
NPI 1306021753
$687.79
in general payments reported to CMS, 2019-2025
12 companies · $23.55 in 2025
The $23.55 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $74.94 · 2022: $113 · 2023: $170 · 2024: $307 · 2025: $23.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $210.79 | 2021-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $121.66 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $102.36 | 2021-2024 | |
| Pfizer INC. | $76.92 | 2021-2024 | |
| Insulet Corporation | $38.85 | 2022-2024 | Omnipod |
| Corcept Therapeutics | $38.00 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $21.90 | 2024 | |
| Medtronic, INC. | $18.09 | 2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $18.07 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.42 | 2024 | Strensiq |
| Lilly USA, LLC | $13.88 | 2023 | Jardiance |
| Amneal Pharmaceuticals LLC | $12.85 | 2023 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.